Our purpose was to evaluate the efficacy and safety of drug-eluting stents in the setting of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI).
Background
There is inconsistent and limited evidence about the efficacy and safety of drug-eluting stents in STEMI patients.
Methods
A single-blind, single-center, randomized study was performed to compare bare-metal stents (BMS) with sirolimus-eluting stents (SES) in 310 STEMI patients. The primary end point was in-segment late luminal loss (LLL) at 9 months. Secondary end points included late stent malapposition (LSM) at 9 months as determined by intravascular ultrasound imaging and clinical events at 12 months.
Results
In-segment LLL was 0.68 Ϯ 0.57 mm in the BMS group and 0.12 Ϯ 0.43 mm in the SES group with a mean difference of 0.56 mm, 95% confidence interval 0.43 to 0.68 mm (p Ͻ 0.001). Late stent malapposition at 9 months was present in 12.5% BMS patients and in 37.5% SES patients (p Ͻ 0.001). Event-free survival at 12 months was 73.6% in BMS patients and 86.0% in SES patients (p ϭ 0.01). The target-vessel-failure-free survival was 84.7% in the BMS group and 93.0% in the SES group (p ϭ 0.02), mainly because of a higher target lesion revascularization rate in BMS patients (11.3% vs. 3.2%; p ϭ 0.006). Rates of death, myocardial infarction, and stent thrombosis were not different.
Conclusions
Sirolimus-eluting stent implantation in STEMI patients is associated with a favorable midterm clinical and angiographic outcome compared with treatment with BMS. However, LSM raises concern about the long-term safety of Percutaneous coronary intervention (PCI) is the preferred revascularization strategy in patients presenting with STsegment elevation myocardial infarction (STEMI) (1) . Percutaneous coronary intervention is directed at restoring coronary flow, stabilizing the ruptured plaque, and reducing infarct size, thereby improving short-and long-term clinical outcome. Implantation of a bare-metal coronary artery stent (BMS) during primary PCI further improves outcome compared with balloon angioplasty alone by reducing the number of acute complications and the restenosis rate (2, 3) . Drug-eluting stents have been proven effective in reducing restenosis in patients with stable and unstable angina (4 -7) . Inconsistent and limited results have been presented about the efficacy and safety of drug-eluting stents in STEMI patients (8, 9) . In particular, stent thrombosis occurring late after implantation of drug-eluting stents, possibly related to late malapposition of the stent struts, has raised safety concerns (10, 11) . Therefore, this randomized prospective study was designed to evaluate midterm angiographic outcome and clinical efficacy of third-generation BMS compared with that seen in sirolimus-eluting stents (SES) in STEMI patients. To address the issue of late stent malapposition (LSM), intravascular ultrasound (IVUS) imaging was performed in both groups at 9-month follow-up.
Methods
Study design. This is a single-center, single-blind, randomized prospective noninferiority study to evaluate clinical, angiographic, and IVUS results in STEMI patients treated with either BMS or SES. The study protocol was approved by the institutional ethical committee. Written informed consent was obtained from all patients before enrollment and before the follow-up catheterization. Patients and operators performing the follow-up angiography were blinded to the treatment assignment. The study was conducted from February 2004 to October 2006. During the study period, all patients were treated according to the institutional STEMI protocol, which included standardized outpatient follow-up (12) . Patient selection. Patients were eligible if STEMI symptoms started Ͻ9 h before the procedure and the electrocardiogram (ECG) demonstrated STEMI (ST-segment elevation Ն0.2 mV in Ն2 contiguous leads in V 1 through V 3 or Ն0.1 mV in other leads, or [presumed] new left bundle branch block). Furthermore, the target lesion length should be Յ24 mm. Exclusion criteria were: 1) age Ͻ18 years or Ͼ80 years; 2) left main stenosis of Ն50%; 3) triple-vessel disease, defined as Ն50% stenosis in Ն3 major epicardial branches; 4) previous PCI or coronary artery bypass grafting of the infarct-related artery; 5) thrombolytic therapy for the index infarction; 5) target vessel reference diameter Ͻ2.25 mm or Ͼ3.75 mm; 6) need for mechanical ventilation; 7) contraindication to the use of aspirin, clopidogrel, heparin, or abciximab; 8) known renal failure; or 9) a life expectancy Ͻ12 months.
After crossing the target lesion with a guidewire and after visual estimation of the target vessel reference diameter, randomization to treatment with a BMS (Vision, Guidant Corp. Indianapolis, Indiana) or SES (Cypher, Cordis Corp., Miami Lakes, Florida) was performed in a 1:1 ratio. Study procedure. Before the procedure all patients received 300 mg of aspirin, 300 to 600 mg of clopidogrel, and an intravenous bolus of abciximab (25 g/kg), followed by a continuous infusion of 10 g/kg/min for 12 h. At start of the procedure, 5,000 IU of heparin was given. Lesions were treated according to current interventional practice. Direct stenting was allowed. If more than 1 stent was required, additional assigned study stents were used. Stent size and length selection was based on visual estimation. Before and immediately after the intervention, 2 angiograms in orthogonal projections were obtained. Intravascular ultrasound imaging was performed after stent implantation (motorized pull-back [0.5 mm/s]), starting Ͼ10 mm distal to the stent and ending at the coronary ostium, using a 2.9-F 20-MHz catheter and a dedicated IVUS console (Eagle Eye, Volcano Corp., Rancho Cordova, California) (13) . Intravascularultrasound-guided stenting was not performed to reflect routine angiographic stent implantation. Each angiogram and ultrasound sequence was preceded by 200 to 300 g of intracoronary nitroglycerin.
Follow-up and data collection.
Patients were seen at the outpatient clinic at 30 days, 3, 6, and 12 months (12). Aspirin (80 to 100 mg/day) was prescribed indefinitely and clopidogrel (75 mg/day) for 12 months. Patients were treated with betablocking agents, statins, and angiotensin-converting enzyme inhibitors or angiotensin II blockers. Follow-up angiography and IVUS imaging was performed at 9 months. Quantitative coronary angiography (QCA) and IVUS analysis. Angiograms were analyzed off-line by analysts blinded for the assigned treatment using validated QCA systems (CMS version 6.1, Medis, Leiden, the Netherlands). Measurements were made in a single projection showing the most severe stenosis following standardized operating procedures (14) . The minimal lumen diameter (MLD) was measured, and the percentage diameter stenosis was calculated using the interpolated reference diameter approach. Late luminal loss (LLL) was defined as the difference between the post-procedural MLD and follow-up MLD. Angiographic restenosis was defined as Ն50% diameter stenosis at 9-months, follow-up.
Intravascular ultrasound images were analyzed off-line, using quantitative IVUS analysis software (QCU-CMS version 4.14, Medis). The stented segment (ϩ5 mm proximally and distally to the stent) was analyzed. The stent and lumen boundaries were determined in all individual frames. In case of malapposition, the stent boundaries were used as lumen boundaries. The volume within the stent and the luminal volume were calculated applying Simpson's rule (15) . Stent malapposition was defined as a separation of at least 1 stent strut, not overlapping a side branch, from the intimal surface with IVUS evidence of blood speckles behind the strut (16, 17) . The site of malapposition was classified as: 1) the body of the stent; 2) the proximal stent edge; or 3) the distal stent edge. Malapposition was persis- Study end points. The primary end point of the study was in-segment LLL at 9-month follow-up angiography. Secondary end points were angiographic restenosis and LSM at 9 months. Additional secondary end points were death, myocardial infarction (MI), target vessel revascularization, target lesion revascularization, target vessel failure, stent thrombosis, procedural success, and clinical success. All deaths were defined as cardiac, unless it was unequivocally proven noncardiac. Myocardial infarction during follow-up was defined as a troponin-T rise Ͼ0.03 g/l with symptoms or PCI, a rise of troponin-T Ͼ0.15 g/l after coronary artery bypass grafting, or a rerise of troponin-T Ͼ25% after recent MI in the presence of symptoms or re-PCI, or the development of new Q waves on ECG (18, 19) . All infarctions were categorized as spontaneous or procedure related (nonindex procedure) (18, 19) . Procedural success was defined as the achievement of Ͻ50% diameter stenosis by QCA with achievement of Thrombolysis In Myocardial Infarction flow grade 3. Clinical success was defined as procedural success without death or reinfarction during the index hospitalization. Target vessel and target lesion revascularization were defined as any revascularization procedure of the target vessel or target lesion (from 5 mm distally to the stent up to 5 mm proximally to the stent), respectively. Clinically driven target lesion revascularization was defined as repeated revascularization procedure of the target lesion (showing Ն50% diameter stenosis) driven by clinical symptoms at rest in conjunction with electrocardiographic evidence of ischemia or a positive stress test (in the presence or absence of clinical symptoms). Target vessel failure was defined as the composite of cardiac death or recurrent MI attributable to the target vessel or any revascularization procedure of the target vessel. If events could not unequivocally be attributed to a nonculprit vessel, they were considered culprit vessel related. Stent thrombosis was defined as angiographically documented thrombus within the stent and/or typical chest pain with recurrent ST-segment elevation in the territory of the infarct-related vessel in combination with a significant rise of troponin levels and/or the presence of new Q waves in the territory of the infarctrelated vessel. Stent thrombosis was classified as acute if it occurred Ͻ24 h after the index procedure, as subacute if it occurred between 1 to 30 days, and as late if it occurred Ͼ30 days (9). All clinical events were adjudicated by a clinical events committee whose members were blinded for the assigned stent type. Statistical design and analysis. The study objective was to assess whether the outcome of treatment with BMS was noninferior to the outcome of treatment with SES. To prove noninferiority, a difference of Յ0.35 mm angiographic in-segment LLL at 9 months was considered clinically insignificant.
The sample size to demonstrate noninferiority of BMS was 244 patients (1-sided) based on the following assumptions: 1) angiographic in-segment LLL at 9 months is 0.40 mm in the SES group and 0.60 mm in the BMS group, with a common within-group standard deviation of 0.40 mm (power 0.90, alpha error of 0.05). To compensate for unsuccessful interventions, crossovers, and losses to follow-up, the sample size was increased to a total of 316 patients. All analyses were conducted according to the intention-to-treat principle. Analysis of post-procedural and follow-up angiographic and IVUS data was conducted according to the number of patients for which complete data were available. 
Results

Patients.
A total of 316 STEMI patients were enrolled in the study (Table 1 , Fig. 1 ). Six patients were subsequently excluded because the assigned study stent was not available, and 310 patients (152 assigned to BMS and 158 assigned to SES) were included in the analysis. With exception of a larger reference diameter in the BMS group, the groups were comparable. One patient crossed over from SES to BMS because of the inability to cross the lesion with the SES. Procedural characteristics are summarized in Table 2 . Angiographic results. Post-procedural and follow-up angiographic data were available for 124 BMS patients (81.6%) and 131 SES patients (82.9%). Patients with and without follow-up angiography had similar baseline characteristics. Six patients without follow-up angiography died during follow-up (4 BMS and 2 SES patients). The median time to angiographic follow-up was 272 days (10th to 90th percentiles: 268 to 295 days) in the BMS group and 272 days (10th to 90th percentiles: 270 to 290 days) in the SES group (p ϭ 0.66). Post-procedural and follow-up QCA results are summarized in Table 5 . The event-free survival was 73.6% in BMS patients and 86.0% in SES patients (HR 1.96, 95% CI 1.17 to 3.30) (Fig. 3A) . During follow-up 6 patients died (1.9%), 4 BMS patients and 2 SES patients (p ϭ 0.44). Recurrent MI occurred in 9.2% of BMS patients and 5.7% of SES patients (p ϭ 0.24); in 7.2% and in 4.4% of the patients this was related to a re-PCI procedure, respectively (p ϭ 0.29). Spontaneous MI, all related to stent thrombosis, occurred in 2.0% of BMS patients and in 1.3% of SES patients (p ϭ 0.68). Target lesion revascularization rate was 11.2% in BMS Baseline Clinical and Angiographic Characteristics (Fig. 3B ). Clinical event rates were not significantly different between patients who underwent follow-up angiography and patients who did not. 
Procedural Characteristics
Discussion
Compared with treatment with BMS, both in-segment LLL and target vessel failure rates were significantly lower after treatment with SES in patients with acute MI. However, after SES implantation LSM was seen more often than after implantation of BMS. Angiographic results. Angiographic in-segment LLL at 9-months' follow-up was chosen as the primary end point, since it reflects the luminal response of the treated segment, including the segments just outside the stent. Late luminal loss is a surrogate but powerful end point to compare the efficacy of stents for the prevention of restenosis (20) . In-segment LLL in the SES group was comparable to the LLL found in the angiographic subgroup of the recently published TYPHOON (Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated With Angioplasty) (9) . The SES LLL was in fact comparable to the LLL in stable angina patients and superior to LLL achieved with BMS in other STEMI studies (2, 5, 6) . The rate of LLL in the BMS group was slightly higher than in the TYPHOON study, which may be explained by the longer implanted stent length in our study. IVUS results. As in patients with stable angina, SES treatment in STEMI patients is associated with negligible neointimal hyperplasia, whereas BMS treatment is associated with significant hyperplasia at follow-up (21) . This finding explains the low angiographic in-stent restenosis rate in the SES group. However, despite excellent angiographic results, a significant rate of LSM (37.5%) was observed in the SES group. The majority of these malappositions was not present immediately after implantation but developed during follow-up, predominantly along the body of the stent (20.2%). The rate of LSM after SES in STEMI patients is even higher than observed in the Results of Quantitative Coronary Angiography Post-Procedure and at Follow-Up Data are expressed as number (%) or mean Ϯ standard deviation. All comparisons between groups were performed with a t test except as indicated (*). Abbreviations as in Table 1 . (5, 22) . In line with our findings, acquired LSM in the SIRIUS study was also mainly located alongside the body of stent (22) . There are only limited data about LSM after stenting in STEMI patients. Hong et al. (23) reported an LSM rate of 11.5% after BMS implantation. In contrast, LSM after drug-eluting stent implantation was present in 31.8% in an observational study of the same group (24) . Late stent malapposition may be caused by 3 different factors: 1) insufficient stent deployment during implantation; 2) resolution of thrombus and/or plaque behind the stent; or 3) positive remodeling of the vessel wall. Persistent LSM, mainly involving the proximal or distal edges of the stents, may be caused by insufficient stent deployment and is thought to be of minor clinical importance (23) . In contrast, acquired LSM, especially when located along the body of the stent, may be due to an adverse effect of the drug on the vessel wall resulting in positive remodeling. This type of LSM cannot be avoided during stent implantation and raises concern about long-term safety, as LSM has been related to very late (Ͼ1 year) stent thrombosis (11, 25) . Clinical outcome. The reduction of target vessel failure rate after SES implantation in STEMI patients was in line with the results of the TYPHOON study (9) . In contrast, 
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Results of Coronary
Ultrasound Analysis at Follow-Up Clinical Events During 12-Months Follow-Up (8) . This difference may be explained by differences in baseline characteristics such as a larger reference diameter and shorter implanted stent length, differences in stent design and drug efficacy, or the lack of angiographic follow-up in the PASSION study (26) . Mortality and MI rates were low in both groups. The MI rate was slightly higher than in the TYPHOON study, possibly because of the strict definitions used in our study. Of interest, the stent thrombosis rate at 12 months was lower and comparable to the results of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent vs. Abciximab and Bare-Metal Stent in Myocardial Infarction) study (comparing SES with tirofiban and BMS with abciximab in STEMI patients) (27) . There were no cases of acute stent thrombosis (Ͻ24 h), possibly because of the intensive antithrombotic regimen applied, including the administration of abciximab in all patients. Late stent thrombosis (Ͼ30 days) occurred in 1 BMS patient (0.7%). Study limitations. With regard to the outcome, the noninferiority design of the study is a relative limitation (28) . At the time of conception of the study, only limited information about the efficacy of SES and third-generation BMS in STEMI patients was available. It was assumed that, despite limited differences in late loss, third-generation BMS were not inferior to drug-eluting stents with regard to efficacy, whereas adverse effects of drug-eluting stents such as LSM and delayed re-endothelialization could be avoided by using BMS (11) . Another limitation is that the angiographic and clinical results of this study cannot be translated into general daily clinical practice, as this was a single-center study in selected patients, and patients were followed using a strict guideline-based follow-up protocol, which is not common practice yet. Moreover, this study was underpowered to detect differences in safety events such as death, recurrent MI, or stent thrombosis. Since IVUS follow-up was not possible in some BMS patients because of restenosis, we cannot exclude that LSM was underestimated in the BMS group, although this is unlikely since these patients had more neointimal growth. Finally, we cannot exclude that the routine angiographic follow-up did result in additional revascularization procedures, magnifying the difference in clinical outcome between BMS and SES.
Conclusions
The SES implantation in STEMI patients is associated with superior midterm clinical and angiographic results compared with BMS implantation. However, LSM is frequently observed in STEMI patients treated with SES, raising concern about long-term safety warranting longterm clinical follow-up. Therefore, based on this study, we cannot recommend or discourage SES use in STEMI patients. 
625
JACC Vol. 51, No. 6, 2008 van der Hoeven et al. February 12, 2008:618-26 SES Versus BMS in STEMI Patients
